precision-oncology-zhcn

Analyze precision oncology questions for specific cancer indications with structured decision support.

33|7|Updated Mar 19, 2026
One-click install
npx skills add https://github.com/patsnap/skills --skill precision-oncology-zhcn
Or copy as Structured Prompt for Agent▼
Please help me install this Agent Skill.
Skill: precision-oncology-zhcn
Source: https://github.com/patsnap/skills/tree/main/life-sciences/precision-oncology-zhcn
Command: npx skills add https://github.com/patsnap/skills --skill precision-oncology-zhcn

SYSTEM DOCUMENTATION & REQUIREMENTS

What problem does it solve?

This Skill helps users answer high-stakes precision oncology questions by connecting cancer biology, epidemiology, standard-of-care therapy, clinical development, and business relevance into one structured analysis.

Core Features & Use Cases

  • Tumor Mechanism Analysis: Explain cancer initiation, progression, signaling changes, and tissue-level pathology.
  • Epidemiology and Patient Segmentation: Summarize incidence, prevalence, subtype distribution, and regional or demographic differences.
  • Standard-of-Care Review: Compare first-line, second-line, and later-line treatments, diagnostics, efficacy metrics, and adverse events.
  • Pipeline and Opportunity Assessment: Identify emerging therapies, unmet needs, and commercial attractiveness for a given indication.
  • Use Case: A biotech team can use this Skill to assess whether a target or modality is compelling for a specific cancer type and how it should be positioned against current therapy.

Quick Start

Ask the skill to evaluate a specific cancer indication, including its biology, epidemiology, current treatment landscape, and emerging therapeutic opportunities.

Frequently Asked Questions about precision-oncology-zhcn

High-intent search queries and answers about installing and using this skill.

FAQPage Schema
How do I analyze precision oncology questions for a specific cancer indication?▼

To analyze precision oncology for a specific cancer indication, integrate literature, epidemiology reports, clinical guidelines, clinical trial data, and biomarker-focused evidence to produce structured decision support.

What is the best way to review standard-of-care treatments and identify unmet needs in oncology?▼

Reviewing standard-of-care oncology treatments requires comparing first-line, second-line, and later-line therapies, diagnostics, efficacy metrics, and adverse events to identify emerging therapies and commercial attractiveness for a given indication.

How do I assess cancer mechanisms and epidemiology for solid tumors and hematologic malignancies?▼

Assessing cancer mechanisms and epidemiology involves explaining cancer initiation, progression, signaling changes, and tissue-level pathology, while summarizing incidence, prevalence, subtype distribution, and regional or demographic differences.

Can I integrate clinical trial data and biomarker evidence to evaluate pipeline opportunities for a specific cancer type?▼

Yes, integrating clinical trial data and biomarker-focused evidence allows you to identify emerging therapies, unmet needs, and commercial attractiveness, helping biotech teams assess whether a target or modality is compelling for a specific cancer type.

Does precision oncology analysis work for both solid tumors and hematologic malignancies?▼

Precision oncology analysis applies to both solid tumors and hematologic malignancies, connecting cancer biology, epidemiology, standard-of-care therapy, clinical development, and business relevance into one structured analysis.